Harmony Biosciences
HRMY
240 hedge funds and large institutions have $2.78B invested in Harmony Biosciences in 2022 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 93 increasing their positions, 65 reducing their positions, and 15 closing their positions.
267% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 15
43% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 65
24% more capital invested
Capital invested by funds: $2.24B → $2.78B (+$541M)
19% more funds holding
Funds holding: 202 → 240 (+38)
0.05% more ownership
Funds ownership: 85.62% → 85.67% (+0.05%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
20% less call options, than puts
Call options by funds: $882K | Put options by funds: $1.11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$38M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$27.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.8M |
| 4 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
+$11M |
| 5 |
D.E. Shaw & Co
New York
|
+$9.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$43.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$25.3M |
| 3 |
Janus Henderson Group
London,
|
-$12.3M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$10.8M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$9.62M |
HRMY Hedge Fund Activity: Q4 2022 in Review
240 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q4 2022, worth a combined $2.78B — up 24% from $2.24B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new HRMY positions and 15 closed out — a net gain of 40 holders — while 93 added to existing stakes and 65 trimmed.
The largest buyer was Aberdeen Group, opening a new position worth an estimated $38M. The largest seller was Vivo Capital, cutting an estimated $43.7M.
- 240 institutional investors held Harmony Biosciences (HRMY) as of Q4 2022, up from 202 in Q3 2022.
- Funds reported $2.78B of Harmony Biosciences stock for Q4 2022, up 24% quarter-over-quarter.
- 55 funds opened new Harmony Biosciences positions in Q4 2022 and 15 closed out, a net change of +40 holders.
- The largest Harmony Biosciences buyer in Q4 2022 was Aberdeen Group, an estimated $38M added.
- The largest Harmony Biosciences seller in Q4 2022 was Vivo Capital, an estimated $43.7M sold.
Based on aggregated 13F filings for Q4 2022.